The value of models in informing resource allocation in colorectal cancer screening: The case of the Netherlands

Gut

Volumn 64, Issue 12, 2015, Pages 1985-1997

  Van Hees, Frank ^a   Zauber, Ann G ^b   Van Veldhuizen, Harriët ^c,d   Heijnen, Marie Louise A ^d   Penning, Corine ^a   De Koning, Harry J ^a   Van Ballegooijen, Marjolein ^a   Lansdorp Vogelaar, Iris ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c 3Erasmus MC ^*  (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER SCREENING; CLINICAL DECISION MAKING; COLONOSCOPY; COLORECTAL CANCER; FECES ANALYSIS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; IMMUNOCHEMISTRY; NETHERLANDS; PRIORITY JOURNAL; RESOURCE ALLOCATION; VALIDATION STUDY; COLORECTAL NEOPLASMS; DECISION SUPPORT SYSTEM; EARLY CANCER DIAGNOSIS; OCCULT BLOOD; PROCEDURES; PROGRAM DEVELOPMENT;

COLORECTAL NEOPLASMS; DECISION SUPPORT TECHNIQUES; EARLY DETECTION OF CANCER; HUMANS; NETHERLANDS; OCCULT BLOOD; PROGRAM DEVELOPMENT; RESOURCE ALLOCATION;

EID: 84954391763     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309316     Document Type: Article

References (60)

1. Schippers EI. Besluit invoering bevolkingsonderzoek naar darmkanker [Decision to implement population screening for colorectal cancer]. 2011. http://www.rivm.nl/Documenten-en-publicaties/Algemeen-Actueel/Uitgaven/Preventie-Ziekte-Zorg/Darmkankerscreening/Brief-besluit-minister-VWS-1-juni-2011 (accessed 19 Jan 2015).
2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
3. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ 2014;348:g2467.
4. Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008;103:1541-9.
5. Gondal G, Grotmol T, Hofstad B, et al. The Norwegian Colorectal Cancer Prevention(NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years. Scand J Gastroenterol 2003;38:635-42.
6. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010;59:62-8.
7. Loeve F, Boer R, van Oortmarssen GJ, et al. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res 1999;32:13-33.
8. van Hees F, Habbema JD, Meester RG, et al. Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. Ann Intern Med 2014;160:750-9.
9. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975;36:2251-70.
10. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
11. Comprehensive Cancer Centre The Netherlands. Dutch Cancer Figures. 2011. http://www.cijfersoverkanker.nl/?language=en (accessed 19 Jan 2015).
12. Arminski TC, McLean DW. Incidence and distribution of adenomatous polyps of the colon and rectum based on 1,000 autopsy examinations. Dis Colon Rectum 1964;7:249-61.
13. Blatt L. Polyps of the colon and rectum: incidence and distribution. Dis Colon Rectum 1961;4:277-82.
14. Bombi JA. Polyps of the colon in Barcelona, Spain. An autopsy study. Cancer 1988;61:1472-6.
15. Chapman I. Adenomatous polypi of large intestine: incidence and distribution. Ann Surg 1963;157:223-6.
16. Clark JC, Collan Y, Eide TJ, et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer 1985;36:179-86.
17. Jass JR, Young PJ, Robinson EM. Predictors of presence, multiplicity, size and dysplasia of colorectal adenomas. A necropsy study in New Zealand. Gut 1992;33:1508-14.
18. Johannsen LG, Momsen O, Jacobsen NO. Polyps of the large intestine in Aarhus, Denmark. An autopsy study. Scand J Gastroenterol 1989;24:799-806.
19. Rickert RR, Auerbach O, Garfinkel L, et al. Adenomatous lesions of the large bowel: an autopsy survey. Cancer 1979;43:1847-57.
20. Stoop EM, de Haan MC, de Wijkerslooth TR, et al. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol 2012;13:55-64.
21. Vatn MH, Stalsberg H. The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer 1982;49:819-25.
22. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 1982;23:835-42.
23. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624-33.
24. Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, et al. A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials. Cancer 2009;115:2410-9.
25. Health Council of the Netherlands. Population screening for colorectal cancer. 2001. http://www.gr.nl/en/publications/preventie/population-screening-for-colorectal-cancer (accessed 19 Jan 2015).
26. Beleidsgroep National Programma Kankerbestrijding. Nationaal Programma Kankerbestrijding 2005-2010 [National Programme Cancer Control 2005-2010]. 2004. http://www.iknlzuid.nl/bibliotheek/index.php?id=1460 (accessed 19 Jan 2015).
27. Signalling committee Cancer of the Dutch Cancer Society. Vroege opsporing van dikkedarmkanker - Minder sterfte door bevolkingsonderzoek [Early detection of colorcal cancer - Lower mortality because of population screening]. 2004. http://repository.kwfkankerbestrijding.nl/PublishingImages/vroege-opsporing-van-dikke-darmkanker.pdf (accessed 19 Jan 2015).
28. Van Ballegooijen M. Screening op colorectaal kanker in Nederland: tijd om te starten [Colorectal cancer screening in the Netherlands - time to start]. 2003.
29. de Visser M, van Ballegooijen M, Bloemers SM, et al. Report on the Dutch consensus development meeting for implementation and further development of population screening for colorectal cancer based on FOBT. Cell Oncol 2005;27:17-29.
30. Hol L, Wilschut JA, van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009;100:1103-10.
31. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135:82-90.
32. Wilschut JA, Hol L, Dekker E, et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 2011;141:1648-55.e1.
33. Mark DH. Visualizing cost-effectiveness analysis. Jama 2002;287:2428-9.
34. Health Council of the Netherlands. A national colorectal cancer screening programme. 2009. http://www.gr.nl/en/publications/preventie/a-national-colorectalcancer-screening-programme (accessed 19 Jan 2015).
35. Klink A. Minister of Health. Standpunt darmkankerscreening [Viewpoint colorect cancer screening]. 2010. http://www.rijksoverheid.nl/bestanden/documenten-enpublicaties/kamerstukken/2010/02/16/standpunt-darmkankerscreening/pg-2984840.pdf (accessed 19 Jan 2015).
36. Nationaal programma kankerbestrijding; werkgroep 2. Bevolkingsonderzoek dikke darmkanker: 'scenarios voor een goede invoering' [Population screening for colorectal cancer: 'scenarios for good implementation']. 2009.
37. van Veldhuizen H, Carpay MEM, van Delden J, et al. Feasibility study into population screening for bowel cancer - Detection of bowel cancer screening put into practice. 2011. http://www.rivm.nl/Documenten-en-publicaties/Wetenschappelijk/Rapporten/2011/juni/Uitvoeringstoets-bevolkingsonderzoek-naar-darmkanker-Opsporing-van-darmkanker-in-praktijk-gebracht (accessed 19 Jan 2015).
38. Centre for Population Screening. Verdiepingsstudies bij de uitvoeringstoets bevolkingsonderzek naar darmkanker [In-depth studies with the feasibility study into population screening for bowel cancer]. 2011. http://www.rivm.nl/Documenten-en-publicaties/Wetenschappelijk/Rapporten/2011/juni/Uitvoeringstoets-bevolkingsonderzoek-naar-darmkanker-Opsporing-van-darmkanker-in-praktijk-gebracht (accessed 19 Jan 2015).
39. National Monitoring and Evaluation Team Colorectal Cancer Screening. Flyer National Monitoring & Evaluation of Colorectal Cancer Screening Programme. 2014. http://www.rivm.nl/en/Documents-and-publications/Common-and-Present/Brochures/Disease-Prevention-and-Healthcare/Bowel-cancer-screening-programme/Flyer-National-Monitoring-Evaluation-of-Colorectal-Cancer-Screening-Programme (accessed 21 Jan 2014).
40. van Veldhuizen H, Marie-Louise Heijnen, Iris Lansdorp-Vogelaar. Adjustment to the implementation of the colorectal cancer screening programme in 2014 and 2015. 2014. http://www.rivm.nl/dsresource?objectid=rivmp:262417&type=org&disposition=inline&ns-nc=1 (accessed 21 Jan 2015).
41. Boer R, Warmerdam P, de Koning H, et al. Extra incidence caused by mammographic screening. Lancet 1994;343:979.
42. Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014;63:317-25.
43. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287-97.
44. Johnson CD, Chen MH, Toledano AY, et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 2008;359:1207-17.
45. Leach CR, Klabunde CN, Alfano CM, et al. Physician over-recommendation of mammography for terminally ill women. Cancer 2012;118:27-37.
46. Saini SD, van Hees F, Vijan S. Smarter screening for cancer: possibilities and challenges of personalization. Jama 2014;312:2211-12.
47. Saini SD, Vijan S, Schoenfeld P, et al. Role of quality measurement in inappropriate use of screening for colorectal cancer: retrospective cohort study. BMJ 2014;348: g1247.
48. Brenner H, Haug U, Hundt S. Sex differences in performance of fecal occult blood testing. Am J Gastroenterol 2010;105:2457-64.
49. Stegeman I, de Wijkerslooth TR, Stoop EM, et al. Risk factors for false positive and for false negative test results in screening with fecal occult blood testing. Int J Cancer 2013;133:2408-14.
50. van den Akker-van Marle ME, van Ballegooijen M, van Oortmarssen GJ, et al. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Canc Inst 2002;94:193-204.
51. Rebolj M, van Ballegooijen M, van Kemenade F, et al. No increased risk for cervical cancer after a broader definition of a negative Pap smear. Int J Cancer 2008;123:2632-5.
52. Cenin DR, St John DJ, Ledger MJ, et al. Optimising the expansion of the National Bowel Cancer Screening Program. Med J Aust 2014;201:456-61.
53. Flanagan WM, Le Petit C, Berthelot JM, et al. Potential impact of population-based colorectal cancer screening in Canada. Chronic Dis Can 2003;24:81-8.
54. Sharp L, Tilson L, Whyte S, et al. Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland. BMC Health Serv Res 2013;13:105.
55. de Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med 2014;160:311-20.
56. Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009;151:738-47.
57. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. An Intern Med 2008;149:659-69.
58. Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, et al. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Canc Inst 2010;102:1238-52.
59. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, et al. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med 2010;153:368-77.
60. Altobelli E, Lattanzi A, Paduano R, et al. Colorectal cancer prevention in Europe: burden of disease and status of screening programs. Prev Med 2014;62:132-41.